Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe.
Merck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in ovarian cancer, denting their hopes of building momentum for the product.
Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ri
Curious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some of the greatest scientists and most accomplished entrepreneurs together on an invite-o
Curious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some of the greatest scientists and most accomplished entrepreneurs together on an invite-o
Curious2018 – Future Insight is a new flagship healthcare conference launched this year by Merck to bring some of the greatest scientists and most accomplished entrepreneurs together on an invite-o